Last reviewed · How we verify
NCT05053685
Metanephrines in Obstructive Sleep Apnoea
trial testing Measurement of Urine and plasma metanephrines in Pheochromocytoma in 81 participants. Completed in 29 August 2023.
29 August 2023
Quick facts
| Lead sponsor | Changi General Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 81 |
| Start date | 29 July 2020 |
| Primary completion | 29 August 2023 |
| Estimated completion | 29 August 2023 |
| Sites | 1 location across Singapore |
Drugs / interventions tested
- Measurement of Urine and plasma metanephrines
Conditions studied
- Pheochromocytoma — all drugs for Pheochromocytoma →
- Obstructive Sleep Apnea — all drugs for Obstructive Sleep Apnea →
- Catecholamine; Secretion — all drugs for Catecholamine; Secretion →
Sponsor
Changi General Hospital
Who can join
Adults 21 to 70, any sex, with Pheochromocytoma or Obstructive Sleep Apnea. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Although most patients have essential (unexplained) hypertension, some patients have a treatable underlying condition. One such condition is phaeochromocytoma, a tumour that produces excessive stress hormones. Left undiagnosed, patients may develop a hypertensive crisis that can be fatal. Measurements of stress hormones (both 24-hour urine collection and morning blood tests) are highly sensitive for detecting these tumours. However, these stress hormones may also be elevated in obstructive sleep apnoea (OSA) which affects 1 in 5 adults. The investigators hypothesize that in patients with OSA, blood tests will be better than 24-hr urine tests at ruling out a tumour. If this is confirmed, then OSA patients with suspected phaeochromocytoma could be investigated with a morning blood test instead of a traditional urine test, reducing unnecessary additional tests and patient anxiety. In this single site study, the investigators plan to recruit 70 patients undergoing polysomnography. 24hr urine and bloods will be measured. Patients with elevated hormone levels will undergo imaging to rule out a tumour. The primary outcome will be the accuracy of each test in ruling out a tumour. The secondary outcomes will be the relationship between stress hormone level and severity of OSA, which may help to explain the increased cardiovascular risk in patients with OSA, and the change in stress hormone level with treatment for OSA
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05053685
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pheochromocytoma
Currently open trials in the same condition.
- NCT06427798 — Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendoc · Phase 1, PHASE2 · recruiting
- NCT07195500 — Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging · recruiting
- NCT06573723 — Institutional Registry of Rare Diseases · recruiting
- NCT06377033 — Using the EHR to Advance Genomic Medicine Across a Diverse Health System · NA · recruiting
- NCT06444607 — Hereditary Pheochromocytoma Assessment of Tumour Immunologies · recruiting
Other Changi General Hospital trials
Trials by the same sponsor.
- NCT07297745 — Trial of Aldosterone-hybrid SteRoid for Guiding curablE Treatment of Primary Aldosteronism (TARGET-PA) · NA · not yet recruiting
- NCT07205133 — A Randomized Controlled Trial Comparing Whole Body Vibration Therapy With Usual Care and Usual Care to Improve Muscle He · NA · recruiting
- NCT06970717 — Programmable Smart Watch for Remote Pre-habilitation/Rehabilitation Monitoring · NA · not yet recruiting
- NCT06890169 — OneSTOP (One-Stop Telehealth Obesity Program) for Multidisciplinary Weight Management and Related Comorbidities · NA · recruiting
- NCT06304415 — Elevated Lipoprotein(a) in Hospital Staff · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05053685 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Changi General Hospital
- Last refreshed: 21 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05053685.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing